Drug Type CAR-T |
Synonyms Anti CD22 chimeric antigen receptor T cell therapy(Shanghai Unicar-Therapy Bio-medicine Technology), CD22CART(Shanghai UnicarTherapy Biomedicine Technology) |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | China | 24 Aug 2017 | |
Non-Hodgkin Lymphoma | Phase 2 | China | 10 May 2017 |